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Summary
There is an urgent and unmet need to develop effective vaccines to reduce 
the global burden of infectious disease in both animals and humans, and 
in particular for the majority of pathogens that infect via mucosal sites. 
Here we summarise the impediments to developing mucosal vaccines and 
review the new and emerging technologies aimed at overcoming the lack 
of effective vaccine delivery systems that is the major obstacle to develop-
ing new mucosal vaccines.
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Introduction
Vaccination is an efficient and cost-effective form of 
infectious disease prevention that can lead to global 
eradication, as seen for smallpox (1980) and rinderpest 
(2011). However, there is an urgent and growing need 
for the development of new and improved vaccines to 
further reduce the global burden of infectious disease 
morbidity and mortality, particularly against those target-
ing the respiratory and gastrointestinal (GI) tract. The 
paucity of effective vaccines is also acute in veterinary 
medicine, which is compounded by increasing multi-drug 
and antibiotic resistance [1]. Vaccines to combat zoonoses 
are a particularly urgent priority, as 60% or more patho-
gens with the potential to harm humans originate in 
animals [2]. Current vaccines are delivered by injection 
with associated problems of safety, compliance, morbidity 
and the high cost of mass immunization, particularly in 
resource-poor developing countries. Injected vaccines also 
provide partial or no protection at mucosal sites. 
Considering that >90% of pathogens gain access to the 
body via mucosal sites, using mucosal vaccination to 
generate protective immunity at mucosal sites could over-
come the limitations of current injection-based vaccines 
in providing front-line protection against pathogen inva-
sion and dissemination [3]. However, only a handful of 
mucosal vaccines are currently licensed. This limited 
availability of mucosal vaccines is related to the lack of 
effective delivery systems able to preserve vaccine antigen 
integrity and strong adjuvanticity, which is compounded 
by the intrinsic nature of the mucosal immune system 
to induce tolerance [4].
Mucosal immunity and vaccine responses
The majority of mucosal vaccines are administered by the 
oral and nasal routes with the vaginal, rectal, ocular and 
sublingual routes being less frequently used. However, not 
all routes of administration induce an equivalent immune 
response in terms of potency and longevity, reflecting 
differences in the organization and cellular make-up of 
lymphoid structures in different mucosal tissues [5,6]. For 
example, oral immunization usually stimulates immune 
responses in the GI tract in addition to the oral mucosa 
and nasal-associated lymphoid tissues (NALT) and mam-
mary glands. Intranasal delivery effectively induces antibody 
production in salivary glands, the NALT and the bronchus-
associated lymphoid tissue (BALT) of the lower respiratory 
tract, and in the urogenital tract. Rectal immunization 
elicits a more pronounced immune and antibody response 
in nasal secretions, tears and the rectal mucosa. Thus, 
depending on the mucosal sites targeted by different 
pathogens, the route of immunization needs to be care-
fully considered [6–8]. In most cases, mucosal vaccination 
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is also effective in priming systemic immune responses 
and generating serum antibodies with neutralizing proper-
ties, reflecting the cross-talk between the mucosal and 
systemic immune systems. Serum immunoglobulin (IgG) 
responses in vaccinated animals can be a useful correlate 
of protection, either alone or in combination with secre-
tory mucosa-derived (IgA) antibodies [9].
Size is another important consideration in the design 
of mucosal vaccines and targeting uptake to inductive 
immune sites to generate T cell and/or B cell responses. 
Goblet cell-associated passageways allow the entry of 
soluble protein antigens, but not inert particles 
(0·02–2  µm) into the underlying lamina propria [10]. Via 
endocytosis, enterocytes readily take up nanosized soluble 
particles of 20–40  nm, whereas M cells are the major 
route by which larger-sized inert particles of more than 
100  nm are taken up [11]. While nanoparticles lead pre-
dominantly to T cell responses, larger microparticles are 
more effective at inducing humoral responses [12,13]. The 
fate of particles delivered via the intranasal route is influ-
enced by their size with particles smaller than 5 µm being 
transported across the nasal mucosa for delivery to cells 
of the BALT. By contrast, larger particles exceeding 10 µm 
are taken up by alveolar macrophages and dendritic cells 
(DCs) [14,15].
Current licensed mucosal vaccine formulations
Human use
The majority of currently licensed human mucosal vac-
cines comprise attenuated strains of pathogenic bacteria 
or viruses that retain their immunogenicity during transit 
through the upper GI tract and can target inductive 
immune sites in the small and large intestine or upper 
respiratory tract (Table 1). The oral polio vaccine, OPV, 
is the most successful mucosal vaccine to date [16]. A 
significant drawback to using attenuated pathogen-based 
vaccines is the risk of reactogenicity and reversion to a 
virulent pathogen following vaccination, usually in immu-
nocompromised infants, elderly people or in individuals 
with a specific immunodeficiency. Although the use of 
OPV has decreased the number of polio cases by more 
than 99% since 1988, there are still disease outbreaks of 
vaccine-associated paralytic polio (VAPP) that arise due 
to small genetic changes occurring during OPV replica-
tion in humans [17,18]. Another concern for live attenu-
ated vaccines is the possibility of retrograde transport to 
the brain after nasal or intranasal vaccination, as happened 
with a replication-defective adenovirus vector carrying 
three proteins from human immunodeficiency virus type 
Table 1. Licensed mucosal vaccines
Target Pathogen Trade name
Delivery route 
(form) Formulation (±adjuvant)
Human Vibrio cholerae Dukoral® Oral (liquid) Inactivated (recombinant 
cholera toxin subunit B)
ShanChol®, Euvichol® Oral (liquid) Inactivated
Vaxchora® Oral (liquid) Live attenuated
Influenza type A and B 
virus
FluMist™ Intranasal 
(spray)
Live attenuated
Poliovirus Biopolio™ B1/3, and other oral polio 
vaccines – OPVs
Oral (liquid) Live attenuated
Rotavirus Rotarix® and RotaTeq® Oral (liquid) Live attenuated
Salmonella 
typhimurium
Typhi Vivotif® Oral (capsules) Live attenuated
Adenovirus Not trade name Oral (tablets) Live attenuated
Approved for military
Animal Rabies virus RABORAL-V-RG Oral (bait) Recombinant  
(Vaccinia virus vector)
Bovine parainfluenza 3 Rispoval Intranasal 
(spray)
Live attenuated
bovine respiratory 
syncytial virus
Bordetella 
bronchiseptica
Nobivac® Intranasal 
(drops)
Live
Canine parainfluenza 
virus
Newcastle disease virus Avinew NeO™ Oral, ocular or 
nasal (spray, 
drinking water 
or drops)
Live attenuated
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1 that was found in the central nervous system of mice 
after intranasal delivery, which may have reached the brain 
via olfactory neurones [19].
Apart from live attenuated vaccines, three World Health 
Organization (WHO) prequalified inactivated oral vaccines 
are in use for cholera (Dukoral®, Shanchol™ and Euvichol®), 
which have been shown to provide high levels (60–95%) 
of long-lived (>2 years) protection in support of the concept 
that non-living vaccines can be effective for mucosal delivery 
and vaccination [20]. Although inactivated vaccines are, in 
general, safe, the process of inactivation (heat and/or formalin 
treatment) can reduce their immunogenicity and require 
the addition of adjuvants such as recombinant cholera toxin 
subunit B, which is included in the Dukoral vaccine [20].
Subunit vaccines comprising synthetic recombinant pep-
tides and proteins, toxoids, DNA or mRNA offer significant 
safety advantages over attenuated and inactivated vaccines. 
They are inert and non-infectious, although they can suffer 
from weak immunogenicity and a requirement for adju-
vants. To date, subunit vaccine formulations have failed 
to confer long-lived protective mucosal immunity in humans 
[21]. The weak immunogenicity of inert molecules and 
protein subunit antigens after delivery to mucosal sites is 
due in large part to their inefficient uptake by the mucosal 
epithelium and delivery to the delivery to the mucosa-
associated lymphoid tissue (MALT) [22,23]. This reflects 
the significant physical, biochemical and microbial obstacles 
orally and nasally administered vaccines must overcome 
in the GI and respiratory tracts in order to access and 
activate mucosal immune cells. During transit through the 
GI tract, vaccine antigens are diluted and can be retained 
or trapped in mucosal secretions and by mucus and be 
subsequently degraded by non-specific host or microbial 
enzymes prior to reaching the mucosal immune system. 
The acidic environment of the upper GI-tract also impacts 
on the stability and integrity of oral vaccines [24]. In the 
respiratory tract, physical discharge due to high mucocil-
lary clearance rates, or peristalsis action in the GI tract, 
also impact upon vaccine integrity and retention time [25].
Veterinary use
Mucosal vaccines have been more successful in the vet-
erinary field, with spray and drinking water vaccines rou-
tinely used for mass vaccination in poultry farming. Recent 
introduction of edible gel-bead-based vaccine systems offer 
a more stable mucosal delivery, protecting live vaccines 
against environmental inactivation to improve bioavailability. 
Use of gel-beads to deliver Eimeria spp. oocysts to day-old 
chicks offers greater uptake of oocysts than water spray 
containing Eimeria spp. oocysts, and significantly higher 
weight gain post-challenge infection [26]. The livestock–
wildlife interface consistently poses difficulties in vaccination 
programmes for animals. Mucosal delivery of vaccines 
through baiting allows free-ranging animals to voluntarily 
uptake vaccines, in order to break down interspecies trans-
mission of infectious disease between wild and domesticated 
animals. Arguably, the most successful bait vaccine is 
RABORAL V-RG® which, following distribution into wildlife 
habitats, has aided eradication of wildlife rabies from 
Belgium, France and Luxembourg [27]. Wildlife bait vac-
cination has also helped to control other pathogens, includ-
ing classical swine fever in wild boar (Sus scrofa) in Europe 
[28] and plague in prairie dogs (Cynomys spp.) in the 
United States [29,30]. Currently, licensed vaccines for par-
enteral application could be administered orally where it 
may not be possible, or feasible, to trap an animal to 
inject them. Mycobacterium bovis is a causative agent of 
tuberculosis (TB), and remains one the most difficult dis-
eases of livestock to control, due largely to the prevalence 
of a wildlife reservoir. Bacillus Calmette–Guérin (BCG) 
vaccines were developed to protect cattle against bovine 
tuberculosis with subsequent experimental and field studies, 
showing that they may be efficacious in the control of M. 
bovis in wild animals after mucosal administration. White-
tailed deer (Odocoileus virginianus) vaccinated with BCG 
Danish strain 1331 by oral bait or oral liquid had fewer 
tuberculosis lesions 5 months post-M. bovis challenge than 
control deer [31]. Badger BCG is a licensed injectable vac-
cine for European badgers (Meles meles) against TB; however, 
capturing animals for injection is labour-intensive and 
stressful. Oral administration of BCG has been shown to 
reduce M. bovis lesions in badgers [32], with 75% of cap-
tured badgers in a further study testing positive for BCG 
vaccine markers where the vaccine was administered in 
bait [33]. Dispersing mucosal vaccines in baits into high-
risk areas could help to reduce endemic TB in wildlife 
reservoirs, reducing the risks of devastating TB outbreaks 
in livestock. Despite promise from field trials, there is still 
a lack of vaccines licensed for distribution into wildlife. 
A major drawback is the risk of non-target species con-
suming the bait; however, with further research into the 
use of subunit or inactivated mucosal vaccines, instead of 
live, this threat may be withdrawn.
The need for human mucosal vaccines
Despite many trials, there are no licensed vaccines for 
many human mucosal-transmitted pathogens (Table 2), 
or the currently available vaccines generate incomplete 
protection.
Improving mucosal vaccines
New technologies are being developed with the aim of 
protecting and preserving antigen structural integrity, as 
well as increasing bioavailability and induction of local 
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and systemic neutralizing immune responses (Table 3). 
All these delivery vehicles can be modified or comple-
mented with immunostimulatory molecules or coating 
agents [e.g. polyethylene glycol (PEG), chitosan] to change 
their charge, adhesive properties, shape, size and/or pH 
to improve their characteristics, interactions with host 
cells and targeting sites of inductive immune responses. 
The incorporation of PEG into polyactide (PLA) nano-
particle vaccine formulations has been shown to be effec-
tive for the oral delivery of hepatitis B surface antigens 
in mice [53]. Chitosan is a biodegradable, biocompatible, 
muco-adhesive, non-toxic polymer that has been used in 
a similar way to protect Escherichia coli  O157:H7 vaccine 
formulations during oral delivery [54].
The inclusion of alginate, polyvinyl alcohol, hyaluronan 
and cellulose to micro- and nanoparticle-based vaccines 
increases their viscosity and augments the retention time 
at mucosal surfaces promoting antigen uptake. Molecules 
that target the carrier or vaccine antigen directly to surface 
receptors on M cells or antigen-presenting cells [e.g. Toll-
like receptors (TLRs)] have also been used [76]. The use 
of adjuvants includes aluminium hydroxide to facilitate 
antibody and T helper type 2 (Th2) CD4 T cell responses, 
or Vibrio cholerae toxin (CT) and heat-labile enterotoxin 
from E. coli to non-specifically boost cellular and humoral 
immune responses [77,78]. To date, recombinant cholera 
toxin subunit B (rCTB) is the only adjuvant accepted for 
inclusion in licensed mucosal vaccines (i.e. Dukoral® vac-
cine). rCTB stimulates the production of both anti-bacterial 
and anti-toxin antibodies without any side effects [79]. 
Genetically modified enterotoxins are being developed to 
reduce toxicity without adversely affecting their 
adjuvanticity.
Plants can be used as bioreactors to produce large 
quantities of vaccine that are then purified from plant 
extracts or can be consumed directly as an edible plant 
vaccine. The plants of choice are rice, lettuce or maize, 
with an edible rice-based cholera vaccine containing rCTB 
(MucoRice-CTB) currently in Phase I clinical trials [80]. 
An experimental lettuce-based hepatitis B virus vaccine 
has been tested in mice and shown to be effective at 
inducing neutralizing antibodies after oral administration 
[81]. Algae are a particularly cost-effective bioreactor option 
for producing large quantities of recombinant vaccines, 
and due to their high structural integrity and resilience 
of their cell walls have the potential to be used intact as 
vaccine delivery vehicles [74]. Chlamydomonas reinhardtii 
has been used in experimental Staphylococcus aureus  vac-
cine formulations [82] and Schizochytrium  sp. have been 
used to develop novel zika virus vaccines [83]; in both 
cases, these algae-based vaccines have been shown to be 
effective at eliciting both mucosal and systemic humoral 
immune responses.
Immunostimulatory complex (ISCOM) technology has 
been incorporated into commercial veterinary vaccines 
such as Equip F® vaccine against equine influenza for 
parenteral delivery, although Ghazi et al. have demonstrated 
protection in mice immunized orally with influenza virus 
subunit vaccines that incorporate ISCOM [84]. Liposomes 
and emulsions carriers have been used in experimental 
vaccines for respiratory virus infections with incorporation 
of the soybean oil-based emulsion W805EC into influenza 
Table 2. Infectious diseases in need of mucosal vaccines
Pathogen Mortality/annum Morbidity/annum Ref.
Respiratory tract
Seasonal influenza 470 000 4 million [34]
RSV-ALRI 128 000 33·8 million [35]
Streptococcus pneumoniae 1·6 million [36]
Mycobacterium tuberculosis 1·6 million 10 million [37]
Gastrointestinal tract
Rotavirus 215 000 [38]
Helicobacter pylori 14 500 [39]
Enterotoxigenic Escherichia coli (ETEC) 400 000 [40,41]
Salmonella 32 000 (Africa) 1 2 million (USA) [42,43]
Shigella 700 000 80 million [44]
Clostridium (difficile/perfringens) 14 000 500 000 [45]
Urogenital tract
Syphilis 205 000 [46]
Gonorrhoea 78 million [47]
Herpes simplex virus 2 417 million [48]
Human papillomavirus (HPV) 270 000 [49]
Hepatitis B 887 000 [50]
Hepatitis C 399 000 71 million [51]
HIV 940 000 36·9 million [52]
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Table 3. Novel mucosal vaccine delivery systems
Delivery system Structure Advantages Limitations Ref.
Liposomes Spherical phospholipid 
bilayer entrapping an 
aqueous solution core
• Ease of incorporating distinct 
types of antigens
• Adaptable physicochemical 
properties
• Lepidic compounds with 
adjuvant properties
• Relatively low intrinsic 
stability for storage and after 
administration
• Potent toxicity of cationic 
lipids (dose-dependent)
[55]
Archaeosomes Liposomes composed of 
Archaea-derived polar 
lipids
• Stable formulations
• Improved immunogenicity 
compared with liposomes
• Preparation and purification 
of Archaea lipids
• Need optimization of 
production and formulation
[56]
Bilosomes Bile salt stabilized vesicles • Stable in gastric environment
• High stability
• Relatively low antigen dose [57]
ISCOM, ISCOMATRIX Cage-like structure 
comprised of cholesterol, 
phospholipids and 
saponin
• Composition, size and surface 
structure like virus
• Self-adjuvanticity due to saponin
• Inclusion of antigens into the 
ISCOM can be difficult
[58]
Bacterial outer membrane 
vesicles (OMV)
OMVs from Gram-negative 
pathogens containing 
microbe-associated 
molecular pattern 
(MAMPs) and membrane 
proteins
• In-built adjuvanticity
• High stability over a wide range 
of temperatures and pH
• Safe use in children and adults 
and effective in controlling 
disease outbreaks
• Chemical detoxification 
required – reduced 
adjuvanticity
• Variable efficacy
• Strain-specific – limited 
heterotypical strain 
protection
[59,60]
Virus-like particles (VLP) Natural virus without 
carrying genetic material
• Highly immunogenic without 
addition of adjuvant
• Antigens can be chemically 
conjugated or genetically 
inserted
• Purification can be a 
challenge
• May have poor quality and 
consistency
• Contamination by host 
materials
[61,62]
Gene gun (DNA 
vaccination)
DNA-coated colloidal gold 
particles
• Fast and simple
• Efficient DNA transduction
• Requires small amounts of DNA 
(0·1 mg/dose)
• Can be used to deliver multiple 
DNAs
• Costly device and reagents
• Limited to exposed tissues
• Depth of penetration versus 
tissue damage
• Preferentially induces T 
helper type 2 response
• Multiple factors influence 
efficacy
[63]
Emulsions Water-in-oil/ 
oil-in-water
Nanosized droplets • Slow release of immunogen
• Ease of manufacture
• Self-adjuvanticity
• Reactogenicity
• Limited stability after 
administration
• Low preservation of antigen 
structure
[64,65]
Synthetic polymer 
nanoparticles (e.g. PLA/
PLGA)
Polylactide (PLA) or 
polylactic-co-glycolic acid 
(PLGA) based nano- and 
micro particles
FDA-approved agents
• Controlled release of antigens
• Biodegradable and biocompatible 
biopolymer
• Sensitivity to harsh gastric 
environment, low loading 
capacity
[66,67]
Natural polymer nanoparti-
cles (e.g. chitosan)
Chitosan based nano- and 
microparticles
• Biocompatible, biodegradable, 
mucoadhesive and 
immunostimulating
• Irregular distribution, low 
physical stability
[68]
Hydrogel (e.g. cCHP 
nanogel)
Cationic cholesterol-bearing 
pullulan nanogel, 
self-assembles with water 
due to their amphiphilic 
polysaccharides
• Ability to function as an artificial 
chaperone
• Prolonged binding to nasal 
epithelium
• Optimization of biodistribu-
tion and degradation 
mechanism
• Component toxicity
[69]
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virus and inactivated respiratory syncytial virus (RSV) 
vaccines, both of which are effective at eliciting protective 
systemic and mucosal antibody immune responses, and 
RSV vaccine also induces cellular immunity after intranasal 
administration [85,86]. Similarly, pneumococcal surface 
protein A (PspA)-based subunit vaccines incorporating a 
cCHP-based nanogel has been shown to induce both 
mucosal and systemic neutralizing antibodies in cynomol-
gus macaques after nasal delivery [87].
Virus-like particles (VLP) are an attractive option as 
a vaccine delivery vehicle due to their  useful proper-
ties, such as the ability to induce adaptive immune response 
and to induce long-term expression of non-self-proteins 
[88,89]. VLPs from adeno-associated viruses (AAV) have 
been used to develop novel influenza virus vaccines encod-
ing camelid-derived anti-influenza antibodies transgenes 
that when administered intranasally protected mice against 
lethal influenza A and B challenge [89,90]. Other preclini-
cal studies using AAV as a carrier include norovirus 
vaccine formulations containing viral protein and RNA, 
that have shown promise in a Phase I clinical trial [91], 
and a chimpanzee-derived AAV expressing hepatitis C 
virus antigens that is currently in Phase II clinical trials 
[92,93].
Gene gun bombardment is a biolistic system for 
mucosal DNA vaccination. This needle-free technology 
is based on propelling DNA-coated colloidal gold micro-
projectiles at exposed tissue surfaces (e.g. skin, vulva 
and mouth) and penetrating the cytosol and cell nucleus 
of cells within deeper layers of the tissue. [94] Epidermal 
DNA vaccines delivered via a gene gun have been shown 
to elicit both humoral and cell-mediated mucosal immune 
responses in experimental animals and cattle [63,95,96]. 
To improve the potency of immune responses gene to 
gun gene immunizations, DNA can be combined with 
adjuvants such as recombinant protein antigens and 
plasmids encoding cytokines [94,97]. However, gene 
gun-mediated delivery has limited or no control over 
where and how effective DNA transduction is in host 
cells and is generally ineffective at inducing immune 
responses of sufficient potency to provide effective and 
long-lived protection.
The use of genetically modified probiotic strains of 
bacteria to deliver vaccine antigens has been explored for 
human papilloma virus (HPV) vaccines. Although a com-
mercial HPV vaccine is available, it does not confer pro-
tection to all HPV-related cancers [49]. Generally 
recognized as safe (GRAS) strains of Lactoccus lacti engi-
neered to express the HPV-16 E6 oncoprotein generated 
humoral and cellular immune response in mice after oral 
administration, as well being shown to have an inhibitory 
effect on tumour growth [98]. There are, however, biosafety 
and environmental contamination concerns in using geneti-
cally modified bacteria [99].
A safer alternative to using viable bacteria as vaccine 
delivery vehicles are non-viable nanometer-sized lipid-
containing microvesicles (outer membrane vesicles; 
OMVs) that are naturally produced and secreted by 
most Gram-negative bacteria [59]. Formulations of 
Neisseria meningitidis OMVs (VA-MENGOC-BC, 
MenBvac, MeNZB and Bexero) have been successfully 
used to vaccinate both adults and children and to con-
trol outbreaks of meningococcal B infection in several 
countries [100,101]. OMVs from other Gram-negative 
pathogens are also promising vaccine candidates, includ-
ing those from Salmonella [102], Shigella flexneri [103] 
and V. cholerae [104]. However, their potential for 
unintended toxicity due to associated toxins is a safety 
concern and limits their widespread use, although chemi-
cal detoxification can overcome this, but at the loss of 
immunogenicity and adjuvanticity [105]. In principle, 
these limitations could be overcome by bioengineering 
the parental bacterium to improve their OMV drug-
delivery capability [60]. Alternatively, non-pathogenic 
Delivery system Structure Advantages Limitations Ref.
Lactic acid bacteria (LAB) Live recombinant LAB 
expressing antigens 
Generally recognized as 
safe (GRAS)
• Easy and safe production and 
storage
• Survives gastric environment
• Self-adjuvanticity
• Safety concerns using 
genetically modified 
organisms
[70]
Chemically processed 
pollen grains (PGs)
Resistant bilayer pollen grain 
shell
• Self-adjuvanted
• Protected from harsh 
environment
• Chemical treatment methods 
required to eliminate 
allergens from pollen grain
[71,72]
Terrestrial plants and algae Plant or algae cells with an 
antigen created by gene 
modification
• Highly resilient cell wall
• Easy manufacturing process and 
scale-up
• Suitable for mass vaccination
• No cold chain requirement
• Use of transgenic plants and 
regulatory body approvals
[73–75]
Modified from Corthesy et al. [54].
Table 3. (Continued)
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commensal bacteria could be used as a source of OMVs 
to reduce toxicity and improve safety. We are develop-
ing an OMV-based drug and biologicals delivery tech-
nology platform based on the use of OMVs produced 
by strains of human commensal Bacteroides engineered 
to express in their OMVs bacterial or viral vaccine 
antigens or human therapeutic proteins for delivery to 
the respiratory and GI tracts.
In summary, while mucosal vaccines represent the ideal 
means of protecting against the majority of infections, 
there are very few licensed vaccines for either humans 
or animals. A raft of new technologies and innovations 
in vaccine antigen encapsulation and delivery are being 
developed to overcome the obstacles of protecting and 
preserving antigen structural integrity as well as increasing 
bioavailability and induction of local and systemic neu-
tralizing immune responses during transit to mucosal 
inductive immune sites, particularly in the GI tract.
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